SLU's knowledge bank

Melatonin and IL-25 induce apoptosis in mammary tumors

Last changed: 02 March 2018
A dog on a lawn. Photo.

Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures.

The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array.


Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments.


This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.

Link to the publication


Gelaleti GB, Borin TF, Maschio-Signorini LB, Moschetta MG, Hellmén E, Viloria-Petit AM, Zuccari DAPC. Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells. Vet Comp Oncol. 2017, 15(4):1572-1584. doi: 10.1111/vco.12303


Eva Hellmén
Professor at the Department of  Anatomy, Physiology and Biochemistry  (AFB); Division of Anatomy and Physiology                                                        

Telephone: 018-672128